AMBUJACEM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.9
| Stock Code | AMBUJACEM | Market Cap | 1,32,700 Cr. | Current Price | 537 ₹ | High / Low | 625 ₹ |
| Stock P/E | 37.0 | Book Value | 206 ₹ | Dividend Yield | 0.37 % | ROCE | 8.80 % |
| ROE | 8.77 % | Face Value | 2.00 ₹ | DMA 50 | 542 ₹ | DMA 200 | 556 ₹ |
| Chg in FII Hold | -0.11 % | Chg in DII Hold | 0.23 % | PAT Qtr | 227 Cr. | PAT Prev Qtr | 1,571 Cr. |
| RSI | 50.5 | MACD | -7.28 | Volume | 10,76,973 | Avg Vol 1Wk | 32,29,311 |
| Low price | 455 ₹ | High price | 625 ₹ | PEG Ratio | 1.79 | Debt to equity | 0.02 |
| 52w Index | 48.2 % | Qtr Profit Var | -87.1 % | EPS | 13.7 ₹ | Industry PE | 30.8 |
📊 Analysis: AMBUJACEM is trading at ₹537, slightly below its 50 DMA (₹542) and 200 DMA (₹556), reflecting short-term weakness. RSI at 50.5 indicates neutral momentum, while MACD (-7.28) shows bearish crossover. Intraday volume (10.7 lakh) is significantly lower than the weekly average (32.3 lakh), suggesting weak participation. Fundamentals show low ROCE (8.80%) and ROE (8.77%), with a sharp quarterly PAT decline (-87.1%). Valuation is stretched (P/E 37.0 vs industry 30.8), though debt-to-equity remains low (0.02). Intraday trading potential is limited, with caution advised.
💡 Optimal Buy Price: ₹530–535 if price consolidates near support.
🎯 Profit-Taking Levels: ₹545–550 (near 50 DMA resistance).
🛡️ Stop-Loss: ₹525 to protect against downside risk.
⏱️ Exit Strategy (if already holding): Exit if price fails to sustain above ₹545 with strong volume. Weak momentum and low participation suggest booking profits early rather than holding for extended moves.
Positive
- Debt-to-equity ratio of 0.02 indicates strong financial stability.
- EPS of ₹13.7 provides earnings visibility.
- DII holding increased by 0.23%, showing domestic institutional support.
- 52-week index return of 48.2% reflects long-term investor interest.
Limitation
- Trading below both 50 DMA and 200 DMA, showing bearish trend.
- Quarterly PAT dropped sharply from ₹1,571 Cr. to ₹227 Cr. (-87.1%).
- Low ROCE (8.80%) and ROE (8.77%) highlight weak efficiency.
- Intraday volume far below average, limiting momentum trades.
- P/E of 37.0 is higher than industry average (30.8).
Company Negative News
- Sharp decline in quarterly profit raises concerns over earnings stability.
Company Positive News
- Debt-free balance sheet ensures financial resilience.
- Stable dividend yield of 0.37% provides some investor return.
Industry
- Industry P/E at 30.8 indicates sector is moderately valued.
- Cement sector benefiting from infrastructure demand and housing growth.
Conclusion
⚖️ AMBUJACEM shows weak intraday momentum and declining earnings, making it a cautious candidate for intraday trading. Entry near ₹530–535 with profit-taking around ₹545–550 is optimal. Traders should closely monitor volume and momentum indicators before committing to positions.